National Securities initiated coverage on Oramed Pharmaceuticals
$ORMP
Biotechnology: Pharmaceutical Preparations
Health Care
National Securities initiated coverage of Oramed Pharmaceuticals with a rating of Buy
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/12/2023 | $30.00 → $3.00 | Buy → Hold | Canaccord Genuity |
2/18/2022 | $20.00 | Overweight | Cantor Fitzgerald |
11/30/2021 | $17.00 → $32.00 | Buy | HC Wainwright & Co. |
11/29/2021 | $17.00 → $32.00 | Buy | HC Wainwright & Co. |
11/2/2021 | $20.00 → $35.00 | Buy | Aegis Capital |
7/29/2021 | $27.00 → $30.00 | Buy | Canaccord Genuity |
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)